Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 12, 1996, Pages 3112-3120

  Venturini, M ^a   Michelotti, A ^a   Del Mastro, L ^a   Gallo, L ^a   Carnino, F ^a   Garrone, O ^a   Tibaldi, C ^a   Molea, N ^a   Bellina, R C ^a   Pronzato, P ^a   Cyrus, P ^a   Vinke, J ^a   Testore, F ^a   Guelfi, M ^a   Lionetto, R ^a   Bruzzi, P ^a   Conte, P F ^a   Rosso, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; RAZOXANE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEART PROTECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 10544231456     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.12.3112     Document Type: Article

References (25)

1. Italian Multicentre Trial: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide vs ftuorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer. J Clin Oncol 6:976-982, 1988
2. Martoni A, Melotti B, Guaraldi M, et al: High-dose epirubicin for untreated patients with advanced tumors: A phase I study. Eur J Cancer 26:1137-1140, 1990
3. Habeshaw T, Paul J, Jones R, et al: Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial. J Clin Oncol 9:295-304, 1991
4. Focan C, Andrien JM, Closon MT, et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253-1263, 1993
5. Levine M, Bramwell V, Bowman D, et al: A clinical trial of intensive CEF versus CMF in premenopausal women with node-positive breast cancer. Proc Am Soc Clin Oncol 14:103, 1995 (abstr)
6. Alderton PM, Gross J, Green MD: Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 52:194-201, 1992
7. Koning J, Palmer P, Franks CR, et al: Cardioxane-ICRF-187. Towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev 18:1-19, 1991
8. Speyer JL, Green MD, Zeleniuch Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992
9. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
10. Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels (ed 8). Boston, MA, Little Brown, 1979
11. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
12. Jain KK, Casper ES, Geller NL, et al: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818-826, 1985
13. Nielsen D, Jensen JB, Dombernowsky P, et al: Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer. J Clin Oncol 8:1806-1810, 1990
14. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 91:710-717, 1979
15. Billingham ME, Bristow MR, Glastein E, et al: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17-23, 1977
16. Valagussa P, Zambetti M, Biasi S, et al: Cardiac effect following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 5:209-216, 1994
17. Lipshultz SE, Lipsitz SR, Mone SM, et al: Female sex and higher drug dose as risk factors for late cardiotoxicity effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
18. Sorensen B, Bastholt L, Mirza MR, et al: The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: A phase I study in metastatic breast cancer. Cancer Chemother Pharmacol 34:439-443, 1994
19. Basser RL, Sobal MM, Duggan G, et al: Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J Clin Oncol 8:1659-1666, 1995
20. Tjuljandin SA, Doig RG, Sobol MM, et al: Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Res 50:5095-5101, 1990
21. Hortobagyi GN, Frye D, Buzdar AU, et al: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63:37-45, 1989
22. Neri B, Pacini P, Algeri R, et al: Conventional versus high-dose epidoxorubicin as single agent in advanced breast cancer. Cancer Invest 11:106-112, 1993
23. Schwartz RG, McKenzie WB, Alexander J, et al: Congestive heart failure and left ventricular dysfunction complicated doxorubicin therapy. Am J Med 82:1109-1118, 1987
24. Allen A: The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 19:529-542, 1992
25. Torti FM, Bristow MM, Lum BL, et al: Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy. Cancer Res 46:3722-3727, 1986